Results 151 to 160 of about 252,758 (328)
Identification of Metabolites of the Dietary Supplement Ingredient 5α‐Hydroxy‐Laxogenin
Drug Testing and Analysis, EarlyView.The biotransformation of the dietary supplement ingredient 5α‐hydroxy‐laxogenin was investigated using human HepG2 cells, the rat and in silico using the online software Next‐gen E‐Resource for Drug Discovery (NERDD). We identified five metabolites generated by the human HepG2 cells of which three and an additional mono‐hydroxylated metabolite were ...
Daniel Derwand +3 more
wiley +1 more source
Commentary: The Dynamic Features of Lip Corners in Genuine and Posed Smiles
Frontiers in Psychology, 2018 Yingqi Li +8 more
doaj +1 more source
Weaning from ketogenic diet therapy in children with epilepsy: Insights from a retrospective study
Epilepsia, EarlyView.Abstract Objective This study was undertaken to describe weaning practices following ketogenic diet therapy (KDT) in children with epilepsy and to identify clinical factors associated with seizure exacerbation or antiseizure medication adjustments during or after weaning from KDT.
Noémie Donnard +10 more
wiley +1 more source
Epilepsia, EarlyView.Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr +6 more
wiley +1 more source
Epilepsia, EarlyView.Abstract Objective GRIN‐related disorders due to pathogenic variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D genes are associated with altered N‐methyl‐D‐aspartate receptor (NMDAR) function. Functional changes include gain (GoF) and loss of receptor function (LoF). Clinical reports describing the use of the NMDAR blocker memantine in GRIN‐related disorders
Maike Karnstedt +17 more
wiley +1 more source
Epilepsia, EarlyView.Abstract Objective The latest European Medicines Agency (EMA) guideline on the clinical investigation of medicines to treat epileptic disorders was adopted by the EMA Committee for Medicinal Products for Human Use in 2025. We compared this guideline with the previous version (2010), highlighting areas where significant revisions were introduced ...
Stéphane Auvin +7 more
wiley +1 more source
Epilepsia, EarlyView.Abstract Objective This study was undertaken to present the results of an exploratory phase 2 trial of stiripentol in Lennox–Gastaut syndrome (LGS). Methods This exploratory single‐blind, single‐arm, nonrandomized sequential‐period phase 2 study was conducted at four centers in France between January 1989 and August 1993.
Stéphane Auvin +3 more
wiley +1 more source